CORT

Corcept Therapeutics Inc

$27.46

+0.45 (+1.67%)

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

15.83

52 wk hi

29.93

Cash

$345.5M

Burn Rate (Qtr)

N/A

Mkt Cap

$2.9b

Avg Volume

633,695

*cash/burn updated:

Q1 '22

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Relacorilant + Nab-paclitaxel

Pancreatic cancer

Phase 3

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Korlym® (Relacorilant)

Hypercortisolism

Phase 3

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Relacorilant + Nab-paclitaxel

Ovarian cancer, Cancer, Solid tumor/s

Phase 3

Update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Miricorilant

Obesity, Antipsychotic-Induced Weight Gain

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Exicorilant (GR antagonist) + Enzalutamide

Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer

Phase 2

Interim update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Miricorilant

Non-alcoholic steatohepatitis

Phase 1b

Interim update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

CORT

BPIQ_Logo_RGB-01.jpg

Company Profile

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.

Recent Posts

See what the community is saying - click to see full post.